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628Results: Patients with SR asthma produced significantly
increased IL-17A and IFN-g levels compared with those in
patients with SS asthma, although it was evident that cells from
individual patients might overproduce one or the other of these
cytokines. Production of IL-17Awas inversely and production of
IL-13 was positively associated with the clinical response to
prednisolone. Oral calcitriol, compared with placebo, therapy of
the patients with SR asthma significantly improved
dexamethasone-induced IL-10 production in vitro while
suppressing dexamethasone-induced IL-17A production. This
effect mirrored the previously demonstrated improvement in
clinical response to oral glucocorticoids in calcitriol-treated
patients with SR asthma.
Conclusions: IL-17Ahigh and IFN-ghigh immunophenotypes exist
in patients with SR asthma. These data identify immunologic
pathways that likely underpin the beneficial clinical effects of
calcitriol in patients with SR asthma by directing the SR
cytokine profile toward a more SS immune phenotype,
suggesting strategies for identifying vitamin D
responder immunophenotypes. (J Allergy Clin Immunol
2015;136:628-37.)
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Asthma is an inflammatory lung disease characterized by
airways hyperresponsiveness and remodeling and is one of
the most common long-term medical conditions. The majority
of asthmatic patients achieve control of their disease with
b2-adrenergic agonists and glucocorticoids (steroids) and
therefore have steroid-sensitive (SS) asthma.1 However, there is
a proportion of patients who do not show improvement in symp-
toms and lung function after compliant treatment with inhaled
steroids, oral steroids, or both; these patients with steroid-
resistant (SR) asthma experience considerable ill health and
impart a considerable financial burden on the health care system.
Asthma is a heterogeneous disease, and phenotype-specific
therapies have been suggested to enhance the likelihood of
therapeutic success in patients relatively refractory to conventional
therapy.2 Recently, significant effort has been directed at defining
severe asthma and, in particular, its endotypes or phenotypes.3
A number of newer biological agents are currently being tested
in clinical trials, and although therapeutic benefit has been
observed with some of them, they appear to target small subsets
of patients.4-9 Furthermore, they are expensive to manufacture
and administer. On the other hand, steroid-sparing or enhancing
strategies for refractory patients remain relatively unexplored.
Asthma historically was characterized as being a CD41
TH2-mediated disease with increased production of IL-4, IL-13,
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identify clinical and immunologic subtypes (phenotypes and
endotypes, including immunophenotypes). For example, there is
established evidence of an IL-17Ahigh phenotype in patients with
severe asthma. Subgroups of patients with severe asthma have
been demonstrated to have increased concentrations of the
proinflammatory cytokine IL-17A in sputum and bronchoalveolar
lavage (BAL) fluid.10-13 Additionally, IL-17A production has
been correlated with airways hyperresponsiveness.14 Although
TH17 cells have been shown to be important for defense against
fungal and bacterial lung infections, a critical balance between
this and an association with various immune pathologies,
including autoimmune disease, appears to exist. Studies in
mice suggest an association between steroid resistance and
TH17-mediated disease: adoptive transfer of TH17 cells resulted
in increased concentrations of chemokines and granulocyte
colony-stimulating factor in the BAL fluid of mice with severe
combined immunodeficiency, and treatment with dexamethasone
resulted in increased neutrophil infiltration but no improvement in
airways hyperresponsiveness.15 More recently, we showed that
blood T-cell IL-17A expression was increased 7-fold in patients
with SR asthma compared with that seen in patients with SS
asthma.16 Additionally, we found that although the synthetic
glucocorticoid dexamethasone did not inhibit IL-17A production,
calcitriol (1,a25-dihydroxyvitamin D [1,25(OH)2D3]), the active
form of vitamin D, significantly inhibited IL-17A production in a
glucocorticoid-independent manner.16 Additionally SR asthma
has been associated with increased expression of the
transcriptionally inactive glucocorticoid receptor b (GR-b),17
whereas increased GR-b expression has been reported in response
to exogenous IL-17A and IL-23 in vitro, an effect that was more
prominent in asthmatic patients than in healthy control
subjects.18,19 Together, these studies constitute a firm platform
for implicating IL-17A in the pathogenesis of SR asthma.
There is a large body of epidemiologic data suggesting
that vitamin D insufficiency, as defined by the serum
25-hydroxyvitamin D (25[OH]D) concentration, is strongly
associated with impaired respiratory health,20 risk of asthma,21,22
asthma severity, and refractoriness to current therapy.23-27 We
have previously shown that patients with SR asthma have a
defective T-cell IL-10 response to dexamethasone in vitro28 and
that this could be restored by 1,25(OH)2D3.
29 These data, along
with the epidemiologic evidence, prompted us to design a
proof-of-concept, placebo-controlled clinical trial assessing
whether treatment with calcitriol could restore clinical
responsiveness to a standard 2-week trial of oral prednisolone
in patients with SR asthma. Indeed, in this trial we showed that
treatment with calcitriol resulted in significant improvement in
steroid responsiveness in these patients.30The aim of the present study was to use PBMC samples from
the patients in this trial to further assess the immunophenotypes of
SS and SR asthma at baseline and after calcitriol therapy in the
patients with SR asthma to identify potential immunophenotypes
of steroid refractoriness and also the likely effect of treatment
with calcitriol.METHODS
Subjects
Asthmatic patients receiving step 3 or 4 therapy according to the British
Thoracic Society guidelines and receiving optimized care by tertiary care
respiratory physicians were recruited and provided written informed consent
(ethics 08/H0804/84). All patients had a prebronchodilator FEV1 of less than
80%of predicted value and documented airway variability of greater than 12%
after 400 mg of short-acting bronchodilator and had undergone detailed
assessment to exclude a diagnosis other than asthma and comorbidities
affecting asthma control. Patients had not received oral glucocorticoids
(steroids) for at least 4 weeks before the study. Patients receiving
immunotherapy, smokers, or patients with a respiratory tract infection or
asthma exacerbation during the 4 weeks before enrollment were excluded.
Steroid resistance was defined as less than 10% improvement in
baseline prebronchodilator FEV1 after a 14-day course of oral prednisolone
(40 mg/1.73 m2/d; Wockhardt UK, Wrexham, United Kingdom) in eligible
patients. Routine spirometry was measured before and after the course of
prednisolone by using a PC-based spirometer and software (WinspiroPRO
Medical International Research, Rome, Italy).
Participants who were identified as having SR asthma were randomized to
receive either 0.25-mg calcitriol soft capsules (Rocaltrol; Roche, Mannheim,
Germany) or organoleptically identical lactose placebo generated in house
(Pharmacy Production Unit, St Thomas’ Hospital NHS Trust, London,
United Kingdom) twice daily for 4 weeks after a 4-week washout period
(full details of the clinical trial study outline and patient details can be found in
the article by Nanzer et al30; see Fig E1 in this article’s Online Repository at
www.jacionline.org for a study schematic). After 2 weeks of calcitriol or
placebo treatment, patients were given a second course of oral prednisolone
identical to the first while calcitriol or placebo was continued. Spirometry
was performed at the beginning and end of this second course of oral
prednisolone, as before.Flow cytometry
The following antibodies were used for ex vivo phenotyping of peripheral
blood obtained from asthmatic donors: CD3, CD4, CD8, and CD19 (SK7,
RPA-T4, RPA-T8, and HIB19, respectively; BD Biosciences, Oxford, United
Kingdom). Red blood cells were lysed after staining with BD FACS lysing
solution; the samples were subsequently assessed on a FACSCalibur
(BD Biosciences). Absolute and differential blood leukocyte counts were
performed routinely with an LH750 hematology analyzer (Beckman Coulter,
Brea, Calif) and analyzed in conjunctionwith flow cytometric data to calculate
cell numbers.Cell isolation and culture
Human PBMCs were isolated, as previously described.29 Briefly,
CD8-depleted PBMCs were obtained by means of negative selection with
CD81 Dynabeads (Invitrogen, Paisley, United Kingdom). Cells (1 3 106
cells/mL) were cultured in RPMI (containing 10% FCS, 2 mmol/L
L-glutamine and 50 mg/mL gentamicin) and stimulated with plate-bound
anti-CD3 (1 mg/mL, OKT-3) plus 50 U/mL recombinant hIL-2 (Eurocetus,
Harefield, United Kingdom) in the presence or absence of dexamethasone at
indicated concentrations (Sigma-Aldrich, Gillingham, United Kingdom)
and/or 10 ng/mL hIL-4 in a 24-well plate for 7 days. There was no significant
difference in cellular viability under all culture conditions (data not shown).
Where indicated, after this initial 7-day period, cells were harvested and
readjusted to the same density of 1 3 106/mL viable cells and then cultured
TABLE I. Patients’ characteristics
Patients with Patients with
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plates, after which supernatants were harvested for cytokine analysis.SS asthma
(n 5 12)
SR asthma
(n 5 23)
P
value
Age (y) 49.0 (40.7-57.3) 51.8 (45.9-57.8)
Ethnic origin
White 9 (75.0) 17 (73.9)
African 3 (25.0) 5 (21.7)Cytokine analysis
IL-17A, IL-10, IFN-g, and IL-13 concentrations in culture supernatants
were measured by using the Cytometric Bead Array (BD Biosciences),
according to themanufacturer’s protocol. The lower limit of detection for each
analyte was 1.5 pg/mL.
Asian 0 1 (4.4)
Sex
Male/female 4 (33.3)/8 (66.6) 14 (60.8)/9 (39.2)
Atopic* 10 (83.3) 19 (82.6)
BMI (kg/m2) 31.8 (28.0-35.6) 28.2 (26.2-30.2) .06
Inhaled corticosteroid
dose (BDP)
1113 (798-1469) 1225 (985-1520) .60
FEV1 (L)
Before steroids 1.7 (1.4-1.9) 1.9 (1.7-2.1) .13Statistics
Data were assessed for equivalence to a Gaussian distribution and equality
of variance, after which the appropriate parametric or nonparametric test was
performed (see individual figure legends) with GraphPad Prism 6 software
(GraphPad Software, La Jolla, Calif). Differences were considered significant
at the 95% confidence level. Data are presented as means, with error bars
representing 95% CIs.
After steroids 2.1 (1.8-2.4) 1.8 (1.6-2.1)
FEV1 (%)
Before steroids 56.0 (47.4-64.6) 61.3 (55.3-67.3) .97
After steroids 70.8 (62.6-79.0) 59.7 (52.8-66.5)
Serum 25(OH)D
(nmol/L)
38.8 (27.6-50.1) 36.9 (27.6-46.2) .51
Where applicable, data are means with 95% CIs or frequencies (percentages). P values
are shown for noncategorical clinical parameters assessed by using an unpaired t test.
BDP, Daily beclomethasone dipropionate equivalent dosage according to the British
Thoracic Society/SIGN guidelines on the management of asthma31; BMI, body mass
index.
*Atopy was defined based on skin prick test responses.RESULTS
To investigate the immunologic phenotypes of SS and SR
asthma, we recruited patients with moderate-to-severe asthma
whowere defined as having either SS or SR asthma based on their
changes in lung function after 2 weeks of therapy with oral
prednisolone at pharmacodynamically uniform dosages (for a
clinical trial schematic, see Fig E1).30 The patients with SS and
SR asthma were similar in terms of demographics, mean body
mass index, mean equivalent inhaled glucocorticoid dosages,
and mean FEV1 at baseline. The only clinical difference between
patients in the 2 groups was their changes in lung function after
oral prednisolone (mean DFEV1 percent predicted); the patients
with SS asthma showed a significant improvement (from 56.0%
[95% CI, 47.4% to 64.6%] to 70.8% [95% CI, 62.6% to
79.0%], P < .0001), whereas the patients with SR asthma did
not (from 61.3% [95% CI, 55.3% to 67.3%] to 59.7% [95% CI,
52.8% to 66.5%], P5 .18; Table I).30,31 There was no significant
difference in mean peripheral blood eosinophil counts in the pa-
tients with SS asthma compared with those in the patients with
SR asthma. Oral prednisolone therapy was associated in both
groups with a significant increase in mean blood neutrophil
counts and a reduction in mean blood eosinophil counts (see
Fig E2 in this article’s Online Repository at www.jacionline.org).Increased expression of IL-17A and IFN-g in patients
with SR asthma compared with patients with SS
asthma
Because asthma is believed to be a CD41 T cell–mediated
disease, we used CD8-depleted PBMC cultures with T-cell
stimulation, as performed in our previous studies,16,29 to compare
T-cell immunophenotypes in both patients with SS and those with
SR asthma. Blood samples for these studies were taken at
screening visit 1 (see Fig E1). CD8-depleted PBMCs from both
groups were cultured for 7 days with anti-CD3 and IL-2 in the
presence or absence of IL-4. After 7 days, cells were washed,
recounted, and replated at 1 3 106/mL to allow for any
differential changes in the numbers of cells between the groups
and stimulated for a further 48 hours. Cytokine protein expression
in culture supernatants was then assessed by using the Cytometric
Bead Array for IL-17A, a TH17 cytokine; IL-13, a TH2 cytokine;
and IFN-g, a TH1 cytokine, as well as the anti-inflammatory
cytokine IL-10. There were no significant differences in ex vivomean numbers of blood T cells (including CD41 and CD81 cells)
and B cells in the asthmatic patients classified as having SS or SR
asthma (see Fig E2, B).
Under these conditions, CD8-depleted PBMCs from the
patients with SR asthma produced significantly increased mean
concentrations of both IL-17A and IFN-g compared with the
those seen in the patients with SS asthma, although the mean
production of IL-10 and IL-13 did not significantly differ. This
difference in IFN-g production between the 2 groups was no
longer observed when exogenous IL-4 was included in the culture
conditions (Table II). Attempts were made to detect IL-17A in the
cultures containing exogenous IL-4, but concentrations were low
or undetectable (data not shown). This is in line with earlier
studies showing that IL-4 inhibited IL-17A production, whereas
anti–IL-4 enhanced IL-17A production from CD41 T cells.32
Conversely, IL-4 signaling through the IL-4 receptor is known
to enhance IL-10 responses.33Differential response to the glucocorticoid
dexamethasone in patients with SR asthma
compared with that in patients with SS asthma
We next examined whether there were differences in
responsiveness to the synthetic steroid dexamethasone in vitro
between patients with SS asthma and patients with SR asthma
that might reflect the differences seen clinically. Cells from the
patients with SR asthma compared with those from the patients
with SS asthma continued to show increased mean production
of IL-17A and IFN-g across a range of dexamethasone
concentrations. Indeed, high concentrations of dexamethasone
further significantly increased IL-17A production by cells from
the patients with SR asthma, a phenomenon not observed in cells
TABLE II. Cytokine production in cultures from both patients with SS and those with SR asthma at baseline
Cytokine
CD3/IL-2
P value
CD3/IL-2 1 IL-4
P valuePatients with SS asthma Patients with SR asthma Patients with SS asthma Patients with SR asthma
IFN-g 11.0 (8.3-13.7) 19.7 (14.2-25.2) .02 8.5 (4.9-12.1) 11.6 (9.0-14.2) .15
IL-10 1.3 (0.2-2.4) 0.8 (0.5-1.2) .51 1.2 (0.5-2.0) 1.6 (0.6-2.6) .61
IL-13 3.6 (0.7-6.6) 2.6 (0.8-4.4) .89 5.1 (1.7-8.6) 4.3 (2.7-5.8) .59
IL-17A 11.3 (1.5-21.0) 47.0 (27.8-66.2) .007 ND ND
Cytokine production (in nanograms per milliliter) by cells either stimulated with CD3 plus IL-2 or additionally in the presence of IL-4 in culture is shown. Data are means and 95%
CIs.
ND, Not detected/measured.
FIG 1. Differential cytokine production by both patients with SS and those with SR asthma in response to
dexamethasone in vitro. Cytokine production by CD8-depleted PBMCs (y-axis) in the presence of
dexamethasone (102x mol/L) in vitro (x-axis) stimulated with CD3 plus IL-2 (A) and additional IL-4 (B) is
shown. Open squares, Patients with SR asthma; solid circles, patients with SS asthma. Data are means
and 95% CIs and assessed by using 2-way ANOVA with Dunnett multiple comparisons tests of cytokine
production in the presence of different concentrations of dexamethasone compared with no
dexamethasone. *P <_ .05, **P < .01, and ***P < .001.
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of IFN-g by cells from the patients with SR asthma was retained
in the presence of dexamethasone, high concentrations of
dexamethasone nevertheless inhibited IFN-g production in both
the patients with SS and those with SR asthma. Dexamethasone
significantly inhibited IL-13 production by cells cultured in the
presence of IL-4 from patients in both groups. Conversely,
dexamethasone increased IL-10 production only in cells from
the patients with SS asthma and strikingly so in the presence of
exogenous IL-4 (P 5 .008), which is in line with our earlier
observations (Fig 1, B).28IL-13 and IL-17A production associate positively and
negatively with clinical responsiveness to
glucocorticoid therapy
We next investigated whether these observed differences
correlated with clinical measurements. Cytokine production
was analyzed according to absolute lung function in both the
patients with SS and those with SR asthma, and there was no
significant association with production of any cytokine (see Fig
E3 in this article’s Online Repository at www.jacionline.org).
However, when the patients with severe asthma were segregated
into quartiles according to their change in lung function after 2
weeks of oral prednisolone therapy (DFEV1 [in liters]), it was
apparent that cells from those asthmatic patients in the lowestquartile whose lung function actually decreased with steroid
therapy produced a significantly increased mean quantity of
IL-17A at baseline compared with those who showed an
improvement. There was a similar trend with IFN-g production,
although this was not statistically significant. Conversely, cells
from those asthmatic patients who were in the upper quartile of
lung function improvement produced a significantly increased
mean quantity of IL-13 at baseline. No such association
was observed with IL-10 production (Fig 2, A), although
those patients whose cells produced the highest mean ratios of
IL-10/IL-17A, as well as IL-13/IL-17A, were more likely to fall
in the upper quartile of the degree in lung function improvement
after taking oral prednisolone (Fig 2, B).Production of IL-17A and IFN-g predict clinical
glucocorticoid responsiveness
Because increasedproductionof both IL-17Aand IFN-g byCD8-
depleted PBMCs was associated with clinical unresponsiveness
to glucocorticoid therapy, we compared production of these
cytokines in the entire population of asthmatic patients (both SS
and SR asthma). Contrary to our expectations, there was no
correlation between overproduction of IL-17A and IFN-g (Fig 3,
A), suggesting that both immunophenotypes contribute to
corticosteroid responsiveness. Indeed, combined production of
both cytokines correlated inversely with change in absolute FEV1
FIG 2. IL-17A is negatively and IL-13 is positively associated with clinical response to 2 weeks of
prednisolone. Cytokine production (A) and ratio of IL-13/IL-17A and IL-10/IL-17A cytokine production
(B) separated based on change in absolute lung function in response to 2 weeks of prednisolone (DFEV1)
are shown. Data are means and 95% CIs and assessed by using Kruskal-Wallis 1-way ANOVA with the
Dunn multiple comparison post hoc statistical test. *P <_ .05 and **P < .01.
FIG 3. IL-17A and IFN-g production predict glucocorticoid responsiveness. A, Comparison of IL-17A and
IFN-g production in patients with SS asthma (solid circles) and patients with SR asthma (open squares).
B, Combined production of IL-17A and IFN-g correlated with change in absolute lung function (DFEV1) in
response to 2 weeks of prednisolone, as assessed by using the Spearman rank correlation statistical test.
C, ROC curves for prediction of steroid resistance based on production of IFN-g, IL-17A, and their
combination.
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FIG 4. Serum 25(OH)D concentration correlates with IL-13 expression in vitro. Cytokine production in
cell-culture supernatants was assessed by using the Cytometric Bead Array and correlated with baseline
vitamin D status (defined as the serum 25[OH]D concentration). A, Cells stimulated with CD3 plus IL-2.
B, Cells stimulated with addition of IL-4 in culture. Open circles, Patients with SR asthma; solid squares,
patients with SS asthma. Data were assessed by using Spearman rank correlation.
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performed analysis of the data in Fig 3, B, in the absence of the po-
tential outlier (withDFEV15 1.34), and interestingly, in the absence
of this point, the correlation was statistically stronger, with a new r
value of20.41 and a P value of .018.
Consequently, we analyzed the sensitivity and specificity of
IL-17A and IFN-g production, both separately and in
combination, to predict the clinical effect of oral prednisolone
therapy in changing FEV1. In the case of IL-17A, receiver oper-
ating characteristic (ROC) analysis was highly significant (P 5
.002): an IL-17A production threshold of greater than 28.1 ng/
mL produced a sensitivity of 63.6% and a specificity of 91.7%
for detecting glucocorticoid resistance. In the case of IFN-g,
ROC analysis provided less robust outcomes (P 5 .06): an IFN-
g production threshold of greater than 20.7 ng/mL produced a
sensitivity of 34.8% and a specificity of 91.7%. The combination
of IL-17A and IFN-g production proved to be a better test: ROC
analysis was highly significant (P 5 .0002), showing that a pro-
duction threshold of greater than 38.5 ng/mL for the sum of
both cytokines predicted clinical glucocorticoid resistance with
a sensitivity of 81.8% and specificity of 91.7% (Fig 3,C). This de-
gree of sensitivity and specificity is at least comparable with that
of noninvasive markers, which have been claimed to predict
glucocorticoid-resistant asthma.34IL-13 production positively correlates with serum
25(OH)D concentrations
Vitamin D has been reported to inhibit lymphocyte production
of IL-17A and IFN-g in vitro16,29,35 while enhancing TH2
cytokine production.36 To examine such possible effects in vivo,
we next compared cytokine production in all of the studyparticipants with their vitamin D status based on serum 25(OH)
D concentrations before calcitriol or placebo therapy. Serum
25(OH)D concentrations did not correlate with production of
IL-10, IL-17A, or IFN-g, but we did observe a significant
positive correlation with IL-13 production that was further
strengthened in the presence of exogenous IL-4 (Fig 4). After
removal of a potential outlier (67 nmol/L; 16 ng/mL), IL-13 still
significantly correlated (r5 0.35; P5 .047) with serum 25(OH)D
levels in the cultures without exogenous IL-4.Calcitriol therapy of patients with SR asthma
reverses induction of IL-17A and augments IL-10
production in response to dexamethasone
In our recent clinical report of the same patients used in the
present study, we showed that treatment of our patients with SR
asthma with calcitriol compared with placebo improved their
clinical responsiveness to glucocorticoid therapy.30 We used
samples collected from these patients, and notably, no difference
was observed between patients with SR asthma subsequently
allocated to either placebo or calcitriol treatment at baseline
before any treatments with regard to their lymphocyte
populations at screening visit 1 (see Fig E2, C). We studied these
patients to establish the possible effect of oral calcitriol therapy on
the immunologic phenotype of peripheral blood cells. We found
that after 4 weeks of therapy with calcitriol/placebo and an
additional identical 2-week course of oral prednisolone for the
final 2 of these 4 weeks (treatment visit 3, see Fig E1), there
was significant induction by dexamethasone of IL-17A
production in the placebo-treated group, as seen at baseline
(screening visit 1). Strikingly, this effect was no longer evident
in the calcitriol-treated group (Fig 5, A). Furthermore, as
FIG 5. Calcitriol treatment decreases expression of IL-17A in cultures from patients with SR asthma.
Cytokine production by CD8-depleted PBMCs from patients with SR asthma in the presence of
dexamethasone (102x mol/L) in vitro after 4 weeks of calcitriol or placebo therapy and 2 weeks of oral
prednisolone therapy and cells stimulated with CD3 plus IL-2 (A) and additional IL-4 (B) is shown.
Open triangles, Calcitriol; solid triangles, placebo. Data are means and 95% CIs. Data were assessed by
using 2-way ANOVA with Dunnett multiple comparisons tests. *P <_ .05, **P < .01, and ***P < .001.
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treated patients with SR asthma now showed a significant
increase in IL-10 production in response to dexamethasone, an
effect that was most marked in the presence of IL-4 in
culture (Fig 5, B). Although IL-13 production correlated with
serum 25(OH)D concentrations at baseline, as shown above, there
was no apparent effect of 4 weeks of calcitriol treatment on
production of IL-13 or its inhibition by dexamethasone. Similarly,
dexamethasone modestly but significantly inhibited IFN-g
production as before and equivalently in the calcitriol- and
placebo-treated patients. Although the numbers are small,
further analysis of the calcitriol-treated patients with SR asthma
showed that the patients whose improvement in lung function
was in the upper quartile in response to the second course of
oral prednisolone were those whose cells produced the
highest mean quantities of IL-13 and the lowest mean quantities
of IL-17A (see Fig E4 in this article’s Online Repository at
www.jacionline.org).DISCUSSION
The data presented in this article demonstrate that there is a
significantly higher production of IL-17A and IFN-g in PBMC
cultures from patients with SR asthma compared with those frompatients with SS asthma. Notably, these appear to reflect 2
distinct immunophenotypes of SR asthma, an IL-17Ahigh and an
IFN-ghigh profile, which are largely nonoverlapping. We have pre-
viously reported,30 and develop here, evidence that glucocorticoids
can aggravate the excessive production of proinflammatory TH17
by blood lymphocytes in patients with SR asthma, which
characterizes a subgroup of these patients. We demonstrate that
the levels of IL-17A synthesis in the PBMC cultures negatively
and IL-13 synthesis positively correlate with the absolute change
in lung function (FEV1) after 2 weeks of oral prednisolone treat-
ment in our adult asthma cohort. Our data further support earlier
findings that TH2
high asthma, as characterized by increased IL-13
production, is more likely to be associated with glucocorticoid
responsiveness.37
The second major finding of this study relates to the capacity of
calcitriol to reverse the SR immune phenotype to one more
closely aligned to that of patients with SS asthma. Thus the
IL-17Ahigh profile is abrogated by calcitriol therapy in a
glucocorticoid-independent manner. Conversely, calcitriol
therapy also restores the impaired, corticosteroid-induced
anti-inflammatory IL-10 response that characterizes patients
with SR asthma, extending our earlier findings in this area.29 In
addition to effects on IL-10 synthesis, calcitriol might reduce
the induction of IL-17A through enhancement of a number of
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pathway and regulatory T cells.16,35,38-40
Several mechanisms have been proposed to contribute to
clinical glucocorticoid refractoriness in asthmatic patients at the
cellular level, particularly in T cells, including overexpression of
proinflammatory transcriptional regulators, such as nuclear factor
kB and activator protein 1; increased expression of histone
deacetylases, polymorphisms of the IL10 gene; increased
expression of the dominant negative isoform of the GR-b;
overexpression of TH2 cytokines; and vitamin D insuffi-
ciency.17,24,25,41-44 More recent evidence also suggests that
IL-17A overexpression can be both a marker and a risk factor
for severe and SR asthma.11-14,16 In this studywe confirm the latter
association and show an independent association with
overexpression of the TH1 cytokine IFN-g. Previous mechanistic
studies in autoimmunemodels of disease have suggested that path-
ologic IL-17A production is by IL-17A1IFN-g1 coexpressing
cells,45-47 but our datawere not consistentwith this, rather suggest-
ing separate ‘‘immunophenotypes’’ of SR asthma. It is notable
from our study that the IL-17Ahigh phenotype might be enhanced
by glucocorticoids in some subjects and that patients with this
phenotypewere more likely to show deterioration in lung function
after oral prednisolone, raising the possibility that oral glucocorti-
coid therapy is not only unhelpful but also detrimental in some of
these patients. Although lymphocyte cultures might not be prac-
tical as routine clinical biomarkers, further research might be
anticipated to reveal more practical novel biomarkers of IFN-ghigh
and IL-17Ahigh SR asthma similarly to the development of perios-
tin as a biomarker of TH2
high asthma.48
The mechanisms behind glucocorticoid enhancement of
IL-17A production by CD4 cells are not fully understood and
represent an area of active research. A recent article described a
detailed transcriptional time course during TH17 differentiation,
suggesting a number of potential candidates for further study.49
Previous data from our laboratory suggest that glucocorticoids
do not inhibit proliferation of IL-17A–expressing cells; the
mechanisms behind these differential effects on proliferation
are unknown and currently under investigation. The differences
observed in this study are not due to differences in the ex vivo
baseline populations of the major lymphocyte groups because
no differences were observed; however, we cannot rule out there
being an enrichment of certain subsets of memory cells. The only
difference we have observed previously was in the frequency of
FoxP3-positive regulatory T cells,39 where we showed that there
was a higher frequency of FoxP3-positive T cells in the peripheral
blood of patients with SS asthma compared with that seen in pa-
tients with SR asthma. However, it seems unlikely that this small
population of cells can account for the large differences observed
in this study.
It is important to note that a somewhat contradictory scientific
literature exists on the capacity of vitamin D to inhibit and/or
enhance TH2 responses experimentally and in animal models
(reviewed by Lange et al50). Our data indicate that serum
concentrations of 25(OH)D positively correlate with IL-13 syn-
thesis in culture. Importantly, however, administration of oral cal-
citriol did not lead to enhancement of IL-13 production in culture.
Although IL-13 is implicated in asthma pathogenesis, its produc-
tion is strongly inhibited by glucocorticoids16,51; indeed, the
TH2
high asthma phenotype is now widely regarded as a marker
of glucocorticoid responsiveness.37 Therefore our data support
the concept that vitamin D improves responsiveness toglucocorticoids at least partly by altering the immunophenotype
away from a glucocorticoid-resistant TH17 phenotype toward a
more responsive TH2 immunophenotype. Thus although calcitriol
does not improve lung function in asthma directly, it does improve
responsiveness to glucocorticoid therapy.30
A limitation to this study was that the data observed were
collected from peripheral blood, although we were able to show
significant correlations between cytokine production in culture
and changes in lung function. Future studies need to be directed at
the target organ to gain full insight into changes in cytokine
expression in these patients. It would be informative to have
studied BAL samples, as well as peripheral blood, providingmore
information about the tissue of interest. However, bronchoscopy
with BAL carries risks and side effects, especially in patients with
severe asthma, and therefore was not part of the current study
design. One approach we took to counteract this limitation was to
perform our peripheral blood cultures in the presence or absence
of IL-4 in an attempt to simulate the TH2-like environment of the
asthmatic bronchial mucosa.52 In our previous work we showed
that the vitamin D–induced effects on IL-10 were most profound
when IL-4 was present in culture.28,40,53
Data from several clinical trials investigating the clinical
efficacy of vitamin D in asthma are emerging.30,54-56 The biggest
published trial to date (408 patients randomized) was the VIDA
trial. In this placebo-controlled trial patients were supplemented
with an initial bolus of 100,000 IU oral vitamin D3 and then
subsequently supplemented with 4,000 IU daily. The primary
outcome was time to first asthma treatment failure, and no
significant improvement in this outcome after vitamin D
supplementation was observed. However, the trial also assessed
changes in the clinical response to inhaled glucocorticoids, and
vitamin D3 supplementation modestly decreased the overall
dose of steroid used.54 Additionally, a striking reduction in the
cumulative number of exacerbations was observed in patients
within the treatment arm. Two recent smaller studies showed a
more positive role for vitamin D supplementation in asthmatic
patients in which vitamin D therapy improved lung function
and reduced asthma exacerbations in the treatment arms
compared with the placebo arm.56,57 Another interesting earlier
trial investigated the effect of vitamin D3 supplementation
(1,200 IU/d) on seasonal influenza A infection and, despite low
numbers, in a secondary outcome measure a significant reduction
in the number of asthma attacks in the group that was receiving
vitamin D3 was reported.55
The studies reported to date have used different forms of
vitamin D at different concentrations and dosing regimens over
varying periods of time. In several studies many patients were not
or were borderline vitamin D deficient, which will affect the
efficacy of vitamin D treatment. Clearly, further investigation is
required to fully understand the effect of vitamin D treatment on
asthma control and prevention. What is unique about our study
was the use of the active form of vitamin D, calcitriol, which we
have previously shown to improve the SR asthmatic response to
2-week prednisolone therapy. Calcitriol is an attractive short-term
adjunct to oral glucocorticoid therapy for severe exacerbations of
disease in patients with SR asthma, particularly those
already taking maintenance oral glucocorticoids. Although
there are concerns about long-term prescription of this form of
vitamin D, short-term therapy might be a viable strategy,
particularly because expression of Cyp27B1, the catalytic
enzyme that converts circulating 25(OH)D into active calcitriol
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58; treatment of
patients with SR asthma with oral calcitriol would bypass this
effect.
In summary, comparison of immunophenotypes in both
patients with SS and those with SR asthma highlights both
IL-17Ahigh and IFN-ghigh immunophenotypes as independent
indicators of glucocorticoid refractoriness and suggests that
calcitriol ameliorates the glucocorticoid responsiveness of
IL-17Ahigh patients. We believe the data from this study, although
from a small cohort, justify further investigation of calcitriol
therapy, and comparison with 25(OH)D supplementation in
patients with SR asthma identified with biomarkers indicative
of nonresponsiveness to glucocorticoids.
Key messages
d IL-17Ahigh and IFN-ghigh immunophenotypes are indica-
tive of SR asthma.
d Calcitriol potentially improves the clinical response to
glucocorticoids through reduction in IL-17A production
and enhancement of steroid-induced IL-10.
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FIG E1. Clinical trial schematic. Patients with severe asthma were recruited
and given prednisolone at screening visit 1 and returned 2 weeks later at
screening visit 2 when patients with SS asthmawere excluded from the trial
and patients with SR asthma were retained. After a 4-week washout period,
the patients with SR asthma were randomly assigned to receive calcitriol or
placebo for 1 month (treatment visit 1). After 2 weeks (treatment visit 2), the
patients were started on additional oral prednisolone and then returned 2
weeks later for the final visit (treatment visit 3). Lung function was assessed
at all clinical trial visits except treatment visit 1. CD8-depleted PBMCs were
assessed from peripheral blood collected at screening visit 1 and treatment
visit 3.
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FIG E2. Peripheral leukocyte counts. A, Peripheral blood total and
differential leukocyte counts in the patients with SS asthma (solid symbols)
and patients with SR asthma (open symbols) before and after 2 weeks of
prednisolone. B and C, Total B cells (CD191), T cells (CD31), and CD41
and CD81 T cells were assessed by using ex vivo flow cytometric analysis
of peripheral blood from screening visit 1 of both patients with SS and
those with SR asthma (Fig E2, B), as well as in the same patients with SR
asthma separated based on their assignment to calcitriol or placebo
treatment (Fig E2, C). Data were assessed by using the Wilcoxon
matched-pairs statistical test (Fig E2, A) or the Mann-Whitney U statistical
test (Fig E2, B and C). *P <_ .05, **P < .01, and ***P < .001.
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FIG E3. A and B, Cytokine production does not associate with lung function. Cytokine production from all
patients with severe asthma separated according to their absolute lung function at baseline (FEV1) is shown.
Data were assessed by using Kruskal-Wallis 1-way ANOVA with the Dunn multiple comparison post hoc
statistical test.
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FIG E4. Effects of calcitriol on lung function and IL-13 and IL-17A levels.
Cytokine production was separated based on individual changes in
absolute lung function (DFEV1) in response to 2 weeks of prednisolone
before (baseline; black bars) and after (after 4 weeks of calcitriol and 2
weeks of prednisolone; white bars) treatment. Numbers of patients with
SR asthma are indicated in parentheses above.
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